Non-Human Primate (NHP) studies remain indispensable for translating preclinical findings into human therapeutics. With their close physiological and metabolic similarity to humans, NHP models provide the most accurate preclinical insights into drug efficacy, pharmacokinetics, and safety.
At Prisys Biotechnologies, we combine decades of NHP pharmacology expertise with artificial intelligence (AI) and machine learning (ML) technologies to deliver precise, quantitative, and ethical preclinical research. Our integrated platform supports pharmaceutical and biotechnology partners across multiple therapeutic areas, from neuroscience and immunology to metabolic and inflammatory disorders.
1. The Role of NHPs in Translational Research
NHPs bridge the gap between rodent studies and human trials. Their comparable anatomy, immune systems, and metabolic pathways enable accurate evaluation of drug responses and safety profiles. Research in NHPs has contributed significantly to the development of treatments for Parkinson's disease, cancer, autoimmune disorders, and infectious diseases.
All NHP studies at Prisys Biotechnologies are conducted in compliance with international ethical standards, ensuring both scientific integrity and animal welfare.
2. Integrating AI and Machine Learning into NHP Research
Prisys Biotechnologies has incorporated AI and ML tools into every stage of NHP research-from data collection to behavioral and imaging analysis-to generate objective, reproducible, and high-resolution datasets.
AI Applications in NHP Studies
Behavioral Video Analysis:
Deep learning algorithms automatically identify and quantify behavioral patterns and emotional states, enabling continuous, unbiased monitoring without physical markers.
Imaging Data Analysis:
ML-assisted MRI and CT data processing allows automatic segmentation and quantification of brain or organ structures, improving the detection of subtle treatment effects in neurological or systemic diseases.
Data Mining:
AI systems analyze multimodal datasets-behavioral, molecular, and imaging-to uncover biological correlations and disease-specific biomarkers that guide therapeutic development.
3. Digital Biomarkers and the NHP Digital Twin
Through continuous monitoring and AI-assisted analysis, Prisys Biotechnologies develops digital biomarkers-quantitative indicators derived from physiological and behavioral data. These biomarkers form the foundation of digital twins, virtual representations of individual animals that enable:
- Early detection of behavioral or physiological changes;
- Quantitative, longitudinal tracking of therapeutic effects;
- Non-invasive and low-stress monitoring that improves reproducibility and animal welfare.
Although digital biomarkers require rigorous validation, their scalability and non-invasive nature make them powerful tools for preclinical research.
4. The AI-Based NHP BehaviorAtlas® System
At the core of Prisys Biotechnologies' innovation is the AI-based NHP BehaviorAtlas® System, a proprietary platform designed to extract and analyze digital behavioral biomarkers, creating a quantitative "Digital NHP Twin."
This system provides objective, high-resolution data for assessing disease progression, therapeutic efficacy, and safety.
Key Features
Continuous, Naturalistic Data Collection
- Markerless Technology:
BehaviorAtlas® employs a markerless, non-invasive approach that eliminates the need for implants or tags, minimizing animal stress and preserving natural behaviors.
- Multi-View, High-Speed 3D Imaging:
Four or more synchronized cameras capture precise motion data from multiple angles for accurate 3D reconstruction.
- Independent Observation Environments:
Experiments are conducted in controlled, human-free observation rooms to prevent behavioral interference.
- Long-Term Monitoring:
Continuous data collection supports longitudinal studies such as chronic disease progression or time-dependent pharmacodynamic effects.
AI/ML-Driven Data Processing
3D Skeletal Reconstruction:
AI algorithms track over 21 anatomical key points with sub-millimeter precision, enabling detailed movement analysis.
Automated Behavioral Classification:
The system identifies and quantifies distinct behaviors-duration, frequency, and sequence-forming precise ethograms.
Digital Twin Creation:
These datasets generate a digital avatar of each animal, allowing quantitative simulation and behavior prediction.
5. Applications of Digital Biomarkers in NHP Research
Prisys Biotechnologies' AI-driven behavioral analytics enable advanced applications across multiple research domains:
- Neuroscience: Quantitative analysis of movement and behavior in Parkinson's disease, ischemic stroke, and epilepsy models.
- Pain Research: Automated detection and quantification of pain-related behaviors in acute and chronic pain models.
- Immunology and Inflammation: Objective measurement of scratching and discomfort behaviors in IL-31-induced pruritus models.
- Motor Function and Mobility: High-precision gait and joint-angle tracking in models of arthritis and other musculoskeletal conditions.
- Safety Pharmacology: Behavioral profiling following CNS-active compound administration, enabling data-driven safety evaluations.
6. Conclusion
By integrating advanced NHP disease models with AI-powered analytics, Prisys Biotechnologies delivers a new standard in quantitative, ethical, and translational preclinical research.
Our NHP BehaviorAtlas® platform provides a unique combination of biological realism and digital precision, enabling researchers to obtain reliable insights that accelerate the development of safe and effective therapeutics.
To explore collaboration opportunities or discuss customized NHP research solutions, please contact Prisys Biotechnologies and discover how our technology can advance your translational research programs.
